Relevant aspects of toxicocardiology


  • Yu.I. Markov Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine



clinical toxicology, cardiotoxicity, cardio-oncology, pharmacotherapy, review


In this review article, various aspects of the development of toxic damage to the cardiovascular system were considered, which commonly occur in clinical practice. Such situations usually happen when several toxic factors (alcohol, illegal drugs, etc.) are combined; if therapeutic doses of cardiotropic drugs are exceeded, or during chemotherapy in oncology. The main pathophysiological mechanisms of action of toxicants on the heart and ways to prevent toxic damage to the cardiovascular system are indicated.


Download data is not yet available.


Джеймс М. Ріттер, Род Флавер, Грем Гендерсон, Юн Конг Лоук, Девід Мак’юен, Гамфрі П. Ранг. Фармакологія за Рангом і Дейлом: пер. 9-го англ. вид.: у 2 т. Т. 1; наук. ред. пер. Г. Зайченко, М. Хайтович. К.: ВСВ «Медицина», 2021. 588 с.

Медицинская токсикология. Под ред. Е.А. Лужникова. М.: ГЭОТАР-Медик, 2014. 928 с.

Марков Ю.І., Недашківський С.М., Лоскутов О.А. Тлумачний словник з клінічної токсикології. К.: ФОП Коляда О.П., 2018. 152 с.

Posadzki P., Watson L., Ernst E. Herb-drug interactions: an overview of systematic reviews. Br. J. Clin. Pharmacol. 2013 Mar. 75(3). Р. 603-618.

Combs A.B., Acosta D. Toxic mechanisms of the heart: a review. Toxicol. Pathol. 1990. 18(4 Pt 1). Р. 583-596.

Phillips K., Luk A., Soor G.S., Abraham J.R., Leong S., Butany J. Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options. Am. J. Cardiovasc. Drugs. 2009. 9(3). Р. 177-196.

Diercks D.B., Kirk J.D., Turnipseed S.D., Amsterdam E.A. Evaluation of patients with methamphetamine- and cocaine-related chest pain in a chest pain observation unit. Crit. Pathw. Cardiol. 2007 Dec. 6(4). Р. 161-164.

Ferrer C.R., Muñiz I.G., Guerrero M.Á.E. et al. Amphetamine and methamphetamine poisonings attended in hospital emergency departments: clinical features and the usefulness of laboratory confirmation. Emergencias. 2020 Feb. 32(1). Р. 26-32.

El-Boghdadly K., Pawa A., Chin K.J. Local anesthetic systemic toxicity: current perspectives. Local Reg. Anesth. 2018, Aug 8. 11. Р. 35-44.

Varga Z.V., Ferdinandy P., Liaudet L., Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 2015 Nov. 309(9). Р. 1453-67.

Nhola L.F., Abdelmoneim S.S., Villarraga H.R., Kohli M., Grothey A., Bordun K.-A., Cheung M., Best R., Cheung D., Huang R., Barros-Gomes S., Pitz M., Singal P.K., Jassal D.S., Mulvagh S.L. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metasta­tic Renal Cell and Colorectal Cancers. J. Am. Soc. Echocardiogr. 2019 Feb. 32(2). Р. 267-276.

Bhagat A., Kleinerman E.S. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv. Exp. Med. Bio. 2020. 1257. Р. 181-192.

Roden D.M. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc. Res. 2019, Apr 15. 115(5). Р. 895-903.

Hutchins K.K., Siddeek H., Franco V.I., Lipshultz S.E. Prevention of cardiotoxicity among survivors of childhood cancer. Br. J. Clin. Pharmacol. 2017 Mar. 83(3). Р. 455-465.

Bansal N., Amdani S.M., Hutchins K.K., Lipshultz S.E. Cardiovascular disease in survivors of childhood cancer. Curr. Opin. Pediatr. 2018 Oct. 30(5). Р. 628-638.

Chandrasekhar S., Fradley M.G. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics. Curr. Treat. Options Oncol. 2019, May 25. 20(7). Р. 55.

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 2020 Aug. 17(8). Р. 474-502.

Romitan D.-M., Rădulescu D., Berindan-Neagoe I., Stoi­cescu L., Grosu A., Rădulescu L., Gulei D., Ciuleanu T.-E. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines. 2020 Nov 12. 8(11). Р. 496.

Jain D., Russell R.R., Schwartz R.G., Panjrath G.S., Aronow W. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions. Curr. Cardiol. Rep. 2017 May. 19(5). Р. 36.

Asnani A. Cardiotoxicity of Immunotherapy: Incidence, Diag­nosis, and Management. Curr. Oncol. Rep. 2018, Apr 11. 20(6). Р. 44.

Jain D., Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp. Pract. 2019 Feb. 47(1). Р. 6-15.

Makavos G., Ikonomidis I., Palios J., Rigopoulos A., Kato­giannis K., Parissis J., Paraskevaidis I., Noutsias M. Cardiac imaging in cardiotoxicity: a focus on clinical practice. Heart Fail. Rev. 2021 Sep. 26(5). Р. 1175-1187.

Hsu C.D., Nichols H.B., Lund J.L. Polypharmacy and medication use by cancer history in a nationally representative group of adults in the USA, 2003–2014. J. Cancer Surviv. 2021 May 25.

Murphy C.C., Fullington H.M., Alvarez C.A., Andrea C.B., Craddock Lee S.J., Haggstrom D.A., Halm E.A. Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer. 2018, Jul 1. 124(13). Р. 2850-2857.

Sutherland J.J., Morrison R.D., McNaughton C.D. et al. Assessment of Patient Medication Adherence, Medical Record Accuracy, and Medication Blood Concentrations for Prescription and Over-the-Counter Medications. JAMA Netw Open. 2018, Nov 2. 1(7). e184196.



How to Cite

Markov, Y. (2022). Relevant aspects of toxicocardiology. EMERGENCY MEDICINE, 18(2), 25–28.



Scientific Review